Assessing the Immunopotency of Toll-like Receptor Agonists in an in Vitro Tissue-engineered Immunological Model

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 2010 Mar 25

PMID 20331478

Citations 14

Authors

Yifan Ma

Louis Poisson

Guzman Sanchez-Schmitz

Santosh Pawar

Chunfeng Qu

Gwendalyn J Randolph

William L Warren

Eric M Mishkin

Russell G Higbee

Affiliations

Soon will be listed here.

Abstract

The in vitro Peripheral Tissue Equivalent (PTE) module is a three-dimensional tissue-engineered endothelial cell/collagen matrix culture system, which has been reported to reproduce in vivo physiological conditions and which generates dendritic cells (DC) autonomously. In the present study, we used the PTE module to investigate the immunopotency of Toll-like receptor (TLR) agonists, including polyinosine-polycytidylic acid, Gardiquimod, CpG 2006 and lipopolysaccharide. Application of TLR agonists in the PTE module induced a wide range of cytokines, including interleukins 1alpha/beta, 6, 8 and 10 and tumour necrosis factor-alpha. Compared with traditional peripheral blood mononuclear cell (PBMC) cultures, the PTE module produced twofold to 100-fold higher levels of cytokine secretion, indicating that it can be a highly sensitive assay system. This increased sensitivity is the result of the natural synergy between the leucocytes and the endothelium. Furthermore, the application of TLR agonists, such as lipopolysaccharide and Gardiquimod, to the PTE module enhanced DC differentiation and promoted DC maturation, as indicated by up-regulated expression of CD83, CD86 and CCR7(CD197). In addition, functional assays indicated PTE-derived DC treated with Gardiquimod, a TLR-7 agonist, significantly augmented anti-tetanus toxoid antibody production. Interestingly, replacing PBMC with purified myeloid cells (CD33(+)) significantly reduced the responsiveness of the PTE module to TLR stimulation. The reduced sensitivity was partly the result of the removal of plasmacytoid DC that participated in the response to TLR stimulation and sensitization of the PTE module. Overall, the in vitro PTE module clearly demonstrated the effects of TLR agonists on DC generation, maturation and antigen-presenting capacity, and may serve as a sensitive and predictive test bed for the evaluation of adjuvant candidates.

Citing Articles

SPA14 liposomes combining saponin with fully synthetic TLR4 agonist provide adjuvanticity to hCMV vaccine candidate.

Luna E, Ruiz S, Garinot M, Chavagnac C, Agrawal P, Escobar J NPJ Vaccines. 2024; 9(1):253.

PMID: 39702373 PMC: 11659416. DOI: 10.1038/s41541-024-01046-0.

Modeling human immune responses to vaccination in vitro.

Morrocchi E, van Haren S, Palma P, Levy O Trends Immunol. 2023; 45(1):32-47.

PMID: 38135599 PMC: 11688643. DOI: 10.1016/j.it.2023.11.002.

A potent novel vaccine adjuvant based on straight polyacrylate.

Garinot M, Piras-Douce F, Probeck P, Chambon V, Varghese K, Liu Y Int J Pharm X. 2020; 2:100054.

PMID: 32776001 PMC: 7398942. DOI: 10.1016/j.ijpx.2020.100054.

Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune model.

Luna E, Agrawal P, Mehta R, Boone M, Vernhes C, Denys C PLoS One. 2018; 13(6):e0197478.

PMID: 29874257 PMC: 5991351. DOI: 10.1371/journal.pone.0197478.

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response.

Edwards D, Jasny E, Yoon H, Horscroft N, Schanen B, Geter T J Transl Med. 2017; 15(1):1.

PMID: 28049494 PMC: 5210268. DOI: 10.1186/s12967-016-1111-6.

References

Smits E, Ponsaerts P, Berneman Z, Van Tendeloo V . The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist. 2008; 13(8):859-75. DOI: 10.1634/theoncologist.2008-0097. View

Baldwin S, Bertholet S, Kahn M, Zharkikh I, Ireton G, Vedvick T . Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine. 2009; 27(23):3063-71. PMC: 2743149. DOI: 10.1016/j.vaccine.2009.03.018. View

Sagara I, Ellis R, Dicko A, Niambele M, Kamate B, Guindo O . A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine. 2009; 27(52):7292-8. PMC: 2808270. DOI: 10.1016/j.vaccine.2009.10.087. View

Hartmann G, Weiner G, Krieg A . CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A. 1999; 96(16):9305-10. PMC: 17777. DOI: 10.1073/pnas.96.16.9305. View

Gorden K, Gorski K, Gibson S, Kedl R, Kieper W, Qiu X . Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005; 174(3):1259-68. DOI: 10.4049/jimmunol.174.3.1259. View

Kadowaki N, Ho S, Antonenko S, Malefyt R, Kastelein R, Bazan F . Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001; 194(6):863-9. PMC: 2195968. DOI: 10.1084/jem.194.6.863. View

Seya T, Akazawa T, Tsujita T, Matsumoto M . Role of Toll-like receptors in adjuvant-augmented immune therapies. Evid Based Complement Alternat Med. 2006; 3(1):31-8. PMC: 1375233. DOI: 10.1093/ecam/nek010. View

Ma Y, Chen Q, Ross A . Retinoic acid and polyriboinosinic:polyribocytidylic acid stimulate robust anti-tetanus antibody production while differentially regulating type 1/type 2 cytokines and lymphocyte populations. J Immunol. 2005; 174(12):7961-9. PMC: 3843132. DOI: 10.4049/jimmunol.174.12.7961. View

Qu C, Moran T, Randolph G . Autocrine type I IFN and contact with endothelium promote the presentation of influenza A virus by monocyte-derived APC. J Immunol. 2003; 170(2):1010-8. DOI: 10.4049/jimmunol.170.2.1010. View

10.

Aguilar J, Rodriguez E . Vaccine adjuvants revisited. Vaccine. 2007; 25(19):3752-62. DOI: 10.1016/j.vaccine.2007.01.111. View

11.

Zhu J, Lai K, Brownile R, Babiuk L, Mutwiri G . Porcine TLR8 and TLR7 are both activated by a selective TLR7 ligand, imiquimod. Mol Immunol. 2008; 45(11):3238-43. DOI: 10.1016/j.molimm.2008.02.028. View

12.

Dockrell D, Kinghorn G . Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother. 2001; 48(6):751-5. DOI: 10.1093/jac/48.6.751. View

13.

Pasare C, Medzhitov R . Toll-like receptors and acquired immunity. Semin Immunol. 2004; 16(1):23-6. DOI: 10.1016/j.smim.2003.10.006. View

14.

Reis e Sousa C . Toll-like receptors and dendritic cells: for whom the bug tolls. Semin Immunol. 2004; 16(1):27-34. DOI: 10.1016/j.smim.2003.10.004. View

15.

Muller W, Weigl S . Monocyte-selective transendothelial migration: dissection of the binding and transmigration phases by an in vitro assay. J Exp Med. 1992; 176(3):819-28. PMC: 2119361. DOI: 10.1084/jem.176.3.819. View

16.

Lutz M, Kukutsch N, OGILVIE A, Rossner S, Koch F, Romani N . An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999; 223(1):77-92. DOI: 10.1016/s0022-1759(98)00204-x. View

17.

Santini S, Di Pucchio T, Lapenta C, Parlato S, Logozzi M, Belardelli F . A new type I IFN-mediated pathway for the rapid differentiation of monocytes into highly active dendritic cells. Stem Cells. 2003; 21(3):357-62. DOI: 10.1634/stemcells.21-3-357. View

18.

Muller W, Randolph G . Migration of leukocytes across endothelium and beyond: molecules involved in the transmigration and fate of monocytes. J Leukoc Biol. 1999; 66(5):698-704. DOI: 10.1002/jlb.66.5.698. View

19.

Assier E, Marin-Esteban V, Haziot A, Maggi E, Charron D, Mooney N . TLR7/8 agonists impair monocyte-derived dendritic cell differentiation and maturation. J Leukoc Biol. 2006; 81(1):221-8. DOI: 10.1189/jlb.0705385. View

20.

Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A . Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol. 2005; 6(8):769-76. PMC: 3760217. DOI: 10.1038/ni1223. View